EYLEA ® (aflibercept) Injection 2 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion ...

In this video, Jay Chhablani, MD, director of clinical research at the UPMC Vision Institute, professor of ophthalmology and ...

ARVO meeting will be held in Salt Lake City, Utah and feature presentation on clinical trials from around the globe.

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

If approved, Eylea would be the first treatment for RVO with 8-week dosing. The FDA target action date is Aug. 19, 2025.

Regeneron (REGN) announces FDA review of sBLA for Eylea HD to treat macular edema and expand dosing. Read more here.

A new study shows that gold nanoparticles injected into the retina can restore vision in mice with retinal degeneration, offering a less invasive alternative to current retinal prostheses.

Biocon Biologics and Regeneron Pharmaceuticals settled to commercialize aflibercept-jbvf in the US, resolving patent ...

Retinal pigment epithelial detachment is associated with neovascular age-related macular degeneration in 30% to 80% of cases, according to the literature.It is often difficult to treat, requires a ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

It's natural for your vision to shift over time. Here are simple ways to care for your eyes, especially this bright, sunny ...

The National Eye Institute reports that age-related macular degeneration, also known as “AMD,” is very common. The condition, which is a disease marked by blurred central vision caused by age-related ...